Candel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)
Candel raised $80 million from investors in part to prepare its aglatimagene BLA. On November 12, 2026, the submission slipped to mid-2027 and CADL fell over 26%, prompting an investigation into potential securities law violations tied to that BLA timeline. NEW YORK, Nov. 16, 2026...